Logo

PALI

Palisade Bio, Inc.

PALI

Palisade Bio, Inc. • NASDAQ
$2.10 ▼ -5.83% (-0.13)
Market Cap $312.91 M
52w High $3.30
52w Low $0.53
Dividend Yield 0%
P/E -1.01
Volume 2.56M
Outstanding Shares 149.00M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.922M ▲ $-2.868M ▼ 0% $-0.38 ▲ $-2.862M ▼
Q2-2025 $0 $2.843M ▲ $-2.784M ▼ 0% $-0.58 ▼ $-2.781M ▼
Q1-2025 $0 $2.31M ▼ $-2.23M ▲ 0% $-0.46 ▲ $-2.228M ▲
Q4-2024 $0 $3.382M ▼ $-3.344M ▲ 0% $-0.57 ▲ $-3.382M ▲
Q3-2024 $0 $3.593M $-3.487M 0% $-2.32 $-3.48M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.227M ▼ $6.973M ▲ $3.761M ▼ $3.212M ▲
Q2-2025 $5.417M ▼ $6.667M ▼ $4.047M ▲ $2.62M ▼
Q1-2025 $7.23M ▼ $8.19M ▼ $2.859M ▼ $5.331M ▼
Q4-2024 $9.821M ▲ $10.88M ▲ $3.388M ▲ $7.492M ▲
Q3-2024 $8.04M $9.336M $2.728M $6.608M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.868M ▼ $-3.553M ▼ $0 $3.363M ▲ $-190K ▲ $-3.553M ▼
Q2-2025 $-2.784M ▼ $-1.817M ▲ $0 $4K ▲ $-1.813M ▲ $-1.817M ▲
Q1-2025 $-2.23M ▲ $-2.333M ▲ $0 $-258K ▼ $-2.591M ▼ $-2.333M ▲
Q4-2024 $-3.344M ▲ $-2.381M ▲ $0 $4.162M ▲ $1.781M ▲ $-2.381M ▲
Q3-2024 $-3.487M $-3.133M $0 $-180K $-3.313M $-3.133M

Five-Year Company Overview

Income Statement

Income Statement Palisade Bio is still a pure development-stage biotech: it has effectively no product revenue and has been running steady operating losses for years. The dollar amounts are small in absolute terms, but for a company this tiny they are still meaningful. Losses have been fairly consistent, reflecting ongoing R&D and overhead rather than any sign of a commercial business. The very large negative earnings per share figures are mainly a function of repeated reverse stock splits and share structure changes, not a sudden collapse in the underlying business. Overall, this is a typical early‑stage biotech income profile: costs, no sales yet, and reliance on outside capital rather than internally generated profits.

Balance Sheet

Balance Sheet The balance sheet is very light: only a thin layer of total assets, mostly cash, and no debt. Equity has recently been positive but was negative a few years ago, which points to prior accumulated losses and recapitalizations. The absence of debt lowers financial strain, but the small absolute cash and asset base means limited cushion if trials extend or costs rise. In practical terms, the company appears solvent but extremely lean, with little margin for major surprises without new financing or partnerships.

Cash Flow

Cash Flow Cash flow is driven almost entirely by spending on operations, especially research and development. Operating cash flows have been consistently negative, and free cash flow mirrors that pattern, since there is essentially no capital spending. The burn rate looks modest in raw dollars but is significant relative to the company’s tiny size. This suggests that continued progress in the pipeline will likely require periodic capital raises or external funding since there is no internal cash generation from products yet.

Competitive Edge

Competitive Edge Palisade operates in a highly competitive area of gastrointestinal and inflammatory diseases where many larger, better‑funded players already market therapies. Its competitive angle is a targeted colon‑activated drug design and a precision medicine approach aimed at selecting patients more likely to respond. This could be differentiating if clinical results remain strong, especially in difficult areas like fibrostenotic Crohn’s disease where options are limited. However, the company’s very small scale, lack of revenue, and dependence on one main clinical asset mean its competitive position is fragile and heavily tied to the success of upcoming trial data and its ability to attract partners or funding.

Innovation and R&D

Innovation and R&D The company’s R&D strategy centers on a specialized prodrug platform for PDE4 inhibitors designed to activate in the colon, aiming to deliver anti‑inflammatory and anti‑fibrotic effects directly to diseased tissue while reducing systemic side effects. Its lead candidate, PALI‑2108, targets ulcerative colitis and fibrostenotic Crohn’s disease, attempting to address both inflammation and scarring, an area with very limited approved treatments. Palisade is also integrating machine learning and biomarker analysis to pre‑select patients, which—if validated—could raise the odds of success and support more personalized treatment. A follow‑on candidate, PALI‑1908, and the precision medicine platform itself provide some pipeline depth, but all of this remains early and clinically risky by nature.

Summary

Palisade Bio is an ultra‑small, clinical‑stage biotech with no commercial revenue, a very lean balance sheet, and steady cash burn typical of early drug developers. Financial strength is modest: no debt is a plus, but the minimal cash and asset base underline continued dependence on external capital. The investment story rests almost entirely on the scientific and clinical potential of its colon‑targeted, precision‑medicine platform in inflammatory bowel disease. If its lead programs continue to show strong safety and efficacy, the company’s technology could stand out in a crowded field, especially in fibrostenotic Crohn’s disease where needs are high. At the same time, trial risk, funding needs, and competition from much larger pharma companies are central uncertainties that dominate the outlook.

NEWS

November 25, 2025 · 8:45 AM UTC

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

Read more

October 28, 2025 · 8:45 AM UTC

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Read more

October 20, 2025 · 11:50 AM UTC

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Palisade Bio, Inc. (NASDAQ: PALI)

Read more

October 20, 2025 · 8:45 AM UTC

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Read more

October 13, 2025 · 8:45 AM UTC

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Read more